Novel target identification technologies for the personalised therapy of type ii diabetes and obesity

Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry

Volumn 12, Issue 3, 2012, Pages 183-207

  Müller, Günter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antidiabetic drugs; Biologicals; Cell reprogramming; Complex diseases; Exosomes; Gene therapy; Genetic prediction; Glycosylphosphatidylinositol anchored proteins; Metabolic diseases; Microvesicles; Nanoparticles; Oral therapy; Regenerative medicine; Tissue engineering; Tissue targeting

Indexed keywords

ADENOVIRUS VECTOR; ARGINYLGLYCYLASPARTIC ACID; BACITRACIN; CAMOSTAT MESILATE; CHITOSAN; COMPLEMENTARY RNA; DECANOIC ACID; DOUBLE STRANDED DNA; GLIMEPIRIDE; GLYCOCHOLATE SODIUM; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; INSULIN; INSULIN DERIVATIVE; LAURIC ACID; MACROGOL; NANOPARTICLE; OCTANOIC ACID; PACLITAXEL; PALMITIC ACID; PARVOVIRUS VECTOR; POLYETHYLENEIMINE; POLYMER; RAD51 PROTEIN; RAD54 PROTEIN; SALICYLATE SODIUM; SMALL INTERFERING RNA; SOYBEAN TRYPSIN INHIBITOR;

ADENO ASSOCIATED VIRUS; ARTICLE; CELL DIFFERENTIATION; CELL THERAPY; CYTOPLASM VESICLE; DNA FOOTPRINTING; DOUBLE STRANDED DNA BREAK; DOWN REGULATION; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TARGETING; EXOSOME; GENE SILENCING; GENETIC ENGINEERING; GENETIC SUSCEPTIBILITY; HUMAN; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIPID RAFT; MALABSORPTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR REPROGRAMMING; OBESITY; OVARY CANCER; PERSONALIZED MEDICINE; PROTEIN MALABSORPTION; RNA EDITING; SIDE EFFECT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WEIGHT GAIN;

EID: 84866389815     PISSN: 18715222     EISSN: 18756115     Source Type: Journal    
DOI: 10.2174/187152212802001866     Document Type: Article

References (264)

1. Edwards, K.L.; Hutter, C.M.; Wan, J.Y.; Kim, H.; Monks, S.A. Genome-wide linkage scan for the metabolic syndrome: The GENNID study. Obesity, 2008, 16, 1596-1601.
2. Weedon, M.N.; McCarthy, M.I.; Hitman, G.; Walker, M.; Groves, C.J.; Zeggini, E. Combining information from common type 2 diabetes risk polymorphisms improves disease prediction. PLoS Med., 2006, 3, e374.
3. Prokopenko, I.; McCarthy, M.J.; Lindgren, C.M. Type 2 diabetes: new genes, new understanding. Trends Genet., 2008, 24, 613-621.
4. Ridderstrale, M.; Groop, L. Genetic dissection of type 2 diabetes. Mol. Cell. Endocrinol., 2009, 297, 10-17.
5. Lindgren, C.M. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nature Clin. Pract., 2007, 4, 156-163.
6. Florez, J.C. The genetics of type 2 diabetes: a realistic appraisal in 2008. J. Clin. Endocrinol. Metab., 2008, 93, 4633-4642.
7. Lusis, A.J.; Attie, A.D.; Reue, K. (2008) Metabolic syndrome: from epidemiology to systems biology. Nature Genet., 2008, 9, 819-830.
8. Gibson, G. Decanalization and the origin of complex disease. Nature, 2009, 10, 134-140.
9. Janssens, A.C.J.W.; van Duijn, C.M. Genome-based prediction of common diseases: advances and prospects. Hum. Mol. Genet., 2008, 17, R166-R173.
10. McCarthy, M.I.; Smedley, D.; Hide, W. New methods for finding disease-susceptibility genes: impact and potential. Genome Biol., 2003, 4, 119.
11. Rothman, K.J.; Greenland, S. Causation and causal interference in epidemiology. Am. J. Pub. Health, 2005, 95(S1), S144-S150.
12. Janssens, A.C.J.W.; Pardo, M.C.; Steyerberg, E.W.; van Dujin, C.M. Revisiting the clinical validity of multiplex genetic testing in complex diseases. Am. J. Hum. Genet., 2004, 74, 585-588.
13. Risch, N.; Merikangas, K. The future of genetic studies of complex human diseases. Science, 1996, 273, 1516-1517.
14. McCarthy, M.I. Growing evidence for diabetes susceptibility genes from genome scan data. Curr. Diab. Rep., 2003, 3, 159-167.
15. Stumvoll, M.; Goldstein, B.J.; van Haeften, T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet, 2005, 365, 1333-1346.
16. Lyssenko, V.; Almgren, P.; Anevski, D.; Orho-Melander, M.; Sjogren, M.; Saloranta, C. Genetic prediction of future type 2 diabetes. PLoS Med. 2005, 2, 1299-1307.
17. Florez, J.C.; Hirschhorn, J.N.; Altshuler, D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu. Rev. Genomics Hum. Genet., 2003, 4, 257-291.
18. Billingsley, M.L. Druggable targets and targeted drugs: Enhancing the development of new therapeutics. Pharmacology, 2008, 82, 239-244.
19. Jain, K.K. Proteomics: delivering new routes to drug discovery - Part 2. Drug Discov. Today, 2001, 6, 829-832.
20. Jain, K.K. Nanodiagnostics: application of nanotechnology in molecular diagnostcs. Expert Rev. Mol. Diagn., 2003, 3, 153-161.
21. Janssens, A.C.J.W.; Gwinn, M.; Subramonia-Lyer, S.; Khoury, M.J. Does genetic testing really improve the prediction of future type 2 diabetes? PLoS Med., 2006, 3, e114.
22. Xiayan, L.; Legido-Quigley, C. Advances in separation science applied to metabonomics. Electrophoresis, 2008, 29, 3724-3736.
23. Figeys, D.; Pinto, D. Proteomics on a chip: Promising developments. Electrophoresis, 2001, 22, 208-216.
24. Müller, G. Concepts and options for current insulin research and future anti-diabetic therapy. Recent Res. Develop. Endocrinol., 2002, 3, 199-218.
25. Powell, A.G.; Apovian, C.M.; Aronne, L.J. New drug targets for the treatment of obesity. Clin. Pharmacol. Therapeut., 2011, 90, 40-51.
26. Burke L.E.; Wang, J. Treatment strategies for overweight and obesity. J. Nurs. Scholarsh., 2011, 43, 1-8.
27. Jain, R.; Chung, S.M.; Jain, L.; Khurana, M.; lau, S.W.J.; Lee, J.E.; Vaidyanathan, J.; Zadezensky, I.; Choe, S.; Sahajwalla, C.G. Implications of obesity for drug therapy: Limitations and challenges. Clin. Pharmacol. Therapeut., 2011, 90, 77-89.
28. Heal, D.J.; Gosden, J.; Smith, S.L. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders. Br. J. Clin. Pharmacol., 2009, 68, 861-874.
29. Niswender, K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diab. Obes. Metab., 2010, 12, 267-287.
30. Witkamp, R.F. Current and future drug targets in weight management. Pharm. Res., 2011, 28, 1792-1818.
31. Field, B.C.T.; Chaudhri, O.B.; Bloom, S.R. Obesity treatment: novel peripheral targets. Br. J. Clin. Pharmacol., 2009, 68, 830-843
32. Sargent, B.J.; Moore, N.A. New central targets for the treatment of obesity. Br. J. Clin. Pharmacol., 2009, 68, 852-860.
33. Müller, G. Personalized prognosis and diagnosis of type II diabetes - vision or fiction? Pharmacology, 2010, 85, 168-187.
34. Grundy, S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat. Rev. Drug Discov., 2006, 5, 295-309.
35. Hsu, Y.-W.; Chu, D.-C.; Ku, P.-W.; Liou, T.-H.; Chou, P. Pharmacotherapy for obesity: Past, present and future. J. Exp. Clin. Med., 2010, 2, 118-123.
36. Frank, R.; Hargreaves, R. Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov., 2003, 2, 566-580.
37. Wang, T.J.; Larson, M.G.; Vasan, R.S.; Cheng, S.; Rhee, E.P.; McCabe, E.; Lewis, G.D:; Fox, C.S.; Jacques P.F.; Fernandez, C.; O'Donnel, C.J.; Carr, S.A.; Mootha, V.K.; Florez, J.C.; Souza, A.; Melander, O.; Clish, C.B.; Gerszten, R.E. Metabolite profiles and the risk of developing diabetes. Nat. Med., 2011, 17, 448-453.
38. Wehling, M. Drug development in the light of translational science: shine or shade. Drug Discov. Today, 2011, 16, 1076-1083.
39. Malandrino, N.; Smith, R.J. Personalized medicine in diabetes. Clin. Chem., 2011, 57, 231-240.
40. Moller, D.E. Metabolic disease drug discovery.- "Hitting the target" is easier said than done. Cell Metabol., 2012, 15, 19-24.
41. Li, M.; Cheung, B.M.Y. Pharmacotherapy for obesity. Br. J. Clin. Pharmacol., 2009, 68, 804-810.
42. Brommage, R.; Desai, U.; Revelli, J.P.; Donoviel, D.B.; Fontenot, G.K.; Dacosta, C.M.; Smith, D.D.; Kirkpatrick, K.J.; Coker, L.L.; Donoviel, M.S.; Eberhart, D.E.; Holt, K.H.; Kelly, M.R.; Paradee, W.J.; Philips, A.V.; Platt, K.A:; Suwanichkul, A.; Hansen, G.M.; Sands, A.T.; Zambrowicz, B.P.; Powell, D.R. High-throughput screening of mouse knockout lines identifies true lean and obese phenotypes. Obesity, 2008, 16, 2362-2367.
43. Sladek, R.; Rocheleau, G.; Rung, J. A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature, 2007, 445, 881-885.
44. Scott, L.J.; Mohlke, K.L.; Bonnycastle, L.L. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science, 2007, 316, 1341-1345.
45. Zeggini, E.; Weedon, M.N.; Lindgren, C.M. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science, 2007, 316, 1336-1341.
46. Dupuis, J.; Langenberg, C.; Prokopenko, I. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet., 2010, 42, 105-116.
47. Hattersley, A.T.; McCarthy, M.I. What makes a good genetic association study? Lancet, 2005, 366, 1315-1323.
48. Kaplan, L.M. Pharmacological therapies for obesity. Gastroenterol. Clin. North. Am., 2005, 34, 91-104.
49. Pearson, E.R.; Starkey, B.J.; Powell, R.J.; Gribble, F.M.; Clark, P.M.; Hattersley, A.T. Genetic cause of hyperglycemia and response to treatment in diabetes. Lancet, 2003, 362, 1275-1281.
50. Rubanyi, G.M. The future of human gene therapy. Mol. Aspect Med. 2001, 22, 113-142.
51. Culver, K.W.; Vickers, T.M.; Lamsam, J.L.; Walling, H.W.; Seregina, T. Gene therapy for solid tumors. Br. Med. Bull., 1995, 51, 192-204.
52. Morgan, R.A.; Anderson W.F. Human gene therapy. Annu. Rev. Biochem., 1993, 62, 191-217.
53. Mulligan, R.C. The basic science of gene therapy. Science, 1993, 260, 926-932.
54. Gottschalk, U.; Chan, S. Somatic gene therapy. Present situation and future perspective. Drug Research, 1998, 48, 1111-1120.
55. Tolstoshev, P. Gene therapy, concepts, current trials and future directions. Annu. Rev. Phrmacol. Toxicol., 1993, 33, 573-596.
56. Wang, Y.; O'malley, B.W.; Tsai, S.Y. Inducible system designed for future gene therapy. Methods Mol. Biol., 1997, 63, 401-413.
57. Wolff, J.A.; Malone, R.W.; Williams, P.; Chong, W.; Acsadi, G.; Jani, A.; Felgner, P.L. Direct gene transfer into mouse muscle in vivo. Science, 1990, 247, 1465-1468.
58. Romano, G.; Claudino, P.P.; Kaiser, H.E.; Giordano, A. Recent advances, prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy. In vivo, 1998, 12, 59-67.
59. Fischer, A. Gene therapy: some results, many problems to solve. Cell Mol. Biol., 2001, 47, 1269-1275.
60. Ma, H.; Diamond, S.L. Nonviral gene therapy and its delivery systems. Curr. Pharm. Biotechnol., 2001, 2, 1-17.
61. Mahato, R.I.; Smith, L.C.; Rolland, A. Pharmaceutical perspectives of nonviral gene therapy. Adv. Gen., 1999, 41, 95-156.
62. Armentano, D.; Sookdeo, C.; Hehir, K.M.; Gregory, R.J.; St. George, J.A.; Prince, G.A.; Wadsworth, S.C.; Smith, A.E. Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther., 1995, 6, 1343-1353.
63. Vile, R.G.; Russell, S.J. Retroviruses as vectors. Br. Med. Bull., 1995, 51, 12-30.
64. Hodgson, C.P. The vector void in gene therapy. Biotechnology, 1995, 13, 222-225.
65. Colton, C.K. Implantable biohybrid artificial organs. Cell Transplant., 1995, 4, 415-436.
66. Eisenberg, R.S. Genomics in the public domain: strategy and policy. Nat. Genet., 2000, 1, 70-74.
67. Li, S.D.; Huang, L. Non-viral is superior to viral gene delivery. J. Control. Rel., 2007, 123, 181-183.
68. Arbit, E. The physiological rationale for oral insulin administration. Diabetes Technol. Ther., 2004, 6, 510-517.
69. Iyer, H.; Khedkar, A.; Verma, M. Oral insulin - a review of current status. Diabetes Obesity Metabol., 2010, 12, 179-185.
70. Kapitza, C.; Zijlstra, E.; Heinemann, L.; Castelli, M.C.; Riley, G.; Heise, T. Oral insulin: A comparison with subcutaneous regular human insulin in patients with type 2 diabetes. Diabetes Care, 2010, 33, 1288-1290.
71. Heinemann, L.; Jacques, Y. Oral insulins and buccal insulins: a critical repraisal. J. Diabetes Sci. Technol., 2009, 3, 568-584.
72. Lasch, F.; Schönbrunner, E. Weitere Untersuchungen über die enterale Insulinresorption, über den Schutz des Insulins gegen Trypsin. Naunyn Schmiedeberg Arch. Pharmacol., 1936, 182, 452-458.
73. Pauletti, G.; Gangwar, S.; Knipp, G.T.; Nerurkar, M.M.; Okuma, F.W.; Tamura, K.; Siahaan, T.J.; Borchardt, R.T. Structural requirements for intestinal absorption of peptide drugs. J. Control. Rel., 1996, 41, 3-17.
74. Wang, W. Oral protein delivery. J. Control. Rel., 1996, 41, 18-24.
75. Woodley, J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug Carrier Syst, 1994, 11, 61-95.
76. Bai, J.P.F.; Chang, L.L. Transepithelial transport of insulin: I Insulin degradation by insulin-degrading enzyme in small intestinal epithelium. Pharm. Res., 1995, 12, 1171-1175.
77. Yamamoto, A.; Taniguchi, T.; Rikyuu, K.; Tsuji, T.; Fujita, T.; Murakami, M.; Muranishi, S. Effects of various protease inhibitors on the intestinal absorption and degradation of insulin in rats. Pharm. Res., 1994, 11, 1496-1500.
78. Abuchowski, A.; McCoy, J.R.; Palczuk, N.C.; van Es, T.; Davis, F.F. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J. Biol. Chem., 1977, 252, 3582-3586.
79. Lowman, A.M.; Morishita, M.; Kajita, M.; Nagai, T.; Peppas, N.A. Oral delivery of insulin using pH-responsive complexation gels. Int. J. Pharm., 1999, 88, 933-937.
80. Hosny, E.A.; Al-Shora, H.H.A.; Elmazar, M.M.A. Oral delivery of insulin from enteric-coated capsules containing sodium salicylate: effect on relative hypoglycaemia of diabetic beagle dogs. Int. J. Pharm., 2002, 237, 71-76.
81. Clement, S.; Still, J.G.; Kosutic, G.; McAllister, R.G. Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol. Ther., 2002, 4, 459-466.
82. Ziv, E.; Lior, O.; Kidron, M. Absorption of protein via the intestinal wall. Biochem. Pharm., 1987, 36, 1035-1039.
83. Carino, P.C.; Mathiowitz, E. Oral insulin delivery. Adv. Drug Deliv. Rev., 1999, 35, 249-257.
84. Palin, K.J.; Philipps, A. J.; Ning, A. The oral absorption of cefoxitin from oil and emulsion vesicles in rats. Int. J. Pharm., 1986, 33, 99-104.
85. Mesiha, M., Plakogiannis, F., and Vejosoth, S. Enhanced oral absorption of insulin from desolvated fatty acid-sodium glycocholate emulsions. Int. J. Pharm., 1994, 111, 213-216.
86. Wang, Y.Z.; Yu, L.; Han, L.; Sha, X.Y.; Fang, X.L. Difunctional pluronic copolymer micelles for paclitaxel delivery: Synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int. J. Pharm., 2007, 337, 63-73.
87. Matsumara, Y. Polymeric micellar delivery systems in oncology. Jpn. J. Clin. Oncol., 2008, 38, 793-802.
88. Fasano, A.; Uzzau, S. Modulation of intestinal tight junctions zona occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. J. Clin. Invest., 1997, 99, 1158-1164.
89. Uhrich, K.E.; Cannizzaro, S.M.; Langer, R.S.; Shakesheff K.M. Polymeric systems for controlled drug release. Chem. Rev., 1999, 99, 3181-3198.
90. Soussan, E.; Cassel, S.; Blanzat, M.; Rico-Lattes, I. Drug delivery by soft matter: Matrix and vesicular carriers. Angew. Chem. Int. Ed. Engl., 2009, 48, 274-288.
91. Ebbesen, M.; Jensen, T.G. Nanomedicine: techniques, potentials, and ethical implications. J. Biomed. Biotechnol., 2006, 5, 51516.
92. Schwendeman, S.P.; Cardamone, M.; Klibanov, A.; Langer, R. Stability of proteins and their delivery from biodegradable polymer microspheres. In: Microparticulate Systems for the Delivery of Proteins and Vaccines; Cohen, S., and Bernstein, H. Eds.; Marcel Dekker, New York, 1996, pp. 1-49.
93. Mathiowitz, E.; Jacob, J.S.; Jong, Y.S.; Carino, G.P.; Chickering, D.E.; Chaturvedi, P.; Santos, C.A.; Vijayaraghavan, K.; Montgomery, S.; Bassett, M.; Morrell, C. Biologically erodible microspheres as potential oral drug delivery systems. Nature, 1997, 386, 410-414.
94. Damge, C.; Michael, C.; Aprahamian, M.; Couvreur, P. New approach for oral administration of insulin with polyalkylcyanoacry-latenanocapsules as oral carrier. Diabetes, 1988, 37, 247-251.
95. Takka, S.; Acarturk, F. Calcium alginate microparticles for oral administration. I: effect of sodium alginate type on drug release and drug entrapment efficiency. J. Microencapsul., 1999, 16, 275-290.
96. Rowsen, M.L.; Dileep, K.J.; Sharma, C.P. Beta cyclodextrin-insulin-encapsulated chitosan/alginate matrix: oral delivery system. J. Appl. Polym. Sci., 2000, 75, 1089-1096.
97. Dapergolas, G.; Gregoriadis, G. Hypoglycaemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet, 1976, 2, 824-827.
98. Gullotti, E.; Yeo, Y. Extracellularly activated nanocarriers: A new paradigm of tumor targeted drug delivery. Mol. Pharmaceut., 2009, 6, 1041-1051.
99. Yokoyama, M. Drug targeting with nano-sized carrier systems. J. Artif. Organs, 2005, 8, 77-84.
100. Lin, Y.H.; Mi, F.L.; Chen, C.T.; Chang, W.C.; Peng, S.F.; Liang, H.F.; Sung, H.W. Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery, Biomacromolecules, 2007, 8, 146-152.
101. Mathiowitz, E. Drug delivery system. Toxicol. Pathol., 2008, 36, 6-22.
102. Yang, T.; Choi, M.K.; Cui, F.D.; Kim, J.S.; Chung, S.J.; Shim, C.K.; Kim, D.D. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. J. Control. Rel., 2007, 120, 169-177.
103. Kirpotin, D.B.; Drummond, D.C.; Shao, Y.; Shalaby, M.R.; Hong, K.L.; Nielsen, U.B.; Marks, J.D.; Benz, C.C.; Park, J.W. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res., 2006, 66, 6732-6740.
104. Mamot, C.; Drummond, D.C.; Noble, C.O.; Kallab, V.; Guo, Z.X.; Hong, K.L.; Kirpotin, D.B.; Park, J.W. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res., 2005, 65, 11631-11638.
105. Dagar, S.; Krishnadas, A.; Rubinstein, I.; Blend, M.J.; Onyuksel, H. VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies. J. Control. Rel., 2003, 91, 123-133.
106. Yang, Y.-Y.; Wang, Y.; Powell, R.; Chan, P. Polymeric core-shell nanoparticles for therapeutics. Clin. Exper. Pharmacol. Physiol., 2006, 33, 557-562.
107. Maeda, H.; Wu, J.; Sawa, T.; Matsumura, Y.; Hori, K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J. Control. Rel., 2000, 65, 271-284.
108. Langer, R. Perspectives: Drugs on target. Science, 2001, 293, 58-59.
109. Chaw, C.S.; Chooi, K.W.; Liu, X.M.; Tan, C.W.; Wang, L.; Yang, Y.Y. Thermally responsive core-shell nanoparticles self-assembled from cholesteryl end-capped and grafted polyacrylamides: Drug incorporation and in vitro release. Biomaterials, 2004, 26, 5064-5074.
110. Liu, S.Q.; Tong, Y.W.; Yang, Y.Y. Incorporation and in vitro re-lease of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions. Biomaterials, 2005, 26, 5064-5074.
111. Lee, E.S.; Na, K.; Bae, Y.H. Super pH-sensitive multifunctional polymeric micelle. Nano Lett., 2005, 5, 325-329.
112. Potineni, A.; Lynn, D.M.; Langer, R.; Amiji, M.M. Poly(ethylene oxide)-modified poly(ß-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J. Control. Rel., 2003, 86, 223-234.
113. Kataoka, K.; Matsumoto, T.; Yokoyama, M. Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: Their pharmaceutical characteristics and biological significance. J. Control Rel. 2000, 64, 143-153.
114. Zhang, Y.; Zhuo, R.X. Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly(ethylene glycol) and polycaprolactone. Biomaterials, 2005, 26, 6736-6742.
115. Zhang, Y.; Zhuo, R.X. Synthesis and drug release behavior of poly(trimethylene carbonate)-poly(ethylene glycol)-poly(trimethylene carbonate) nanoparticles. Biomaterials, 2005, 26, 2089-2094.
116. Dong, Y.; Feng, S.S. Poly(D,L-lactide-co-glycolide)/montmoril-lonite nanoparticles for oral delivery of anticancer drugs. Biomaterials, 2005, 26, 6068-6076.
117. Zambaux, M.F.; Bonneaux, F.; Gref, R. Influence of experimental parameters on the characteristics of poly(lactic acid) nanoparticles prepared by double emulsion method. J. Control. Rel., 1998, 50, 31-40.
118. Yoo, H.S.; Park, T.G. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J. Control. Rel., 2004, 96, 273-283.
119. Wei, J.S.; Zeng, H.B.; Liu, S.Q.; Wang, X.G.; Tay, E.H.; Yang, Y.Y. Temperate- and pH-sensitive core-shell nanoparticles self-assembled from poly/N-isopropylacrylamide-co-acryl acid-co-cholesteryl acrylate) for intracellular delivery of anticancer drugs. Front. Biosci., 2005, 10, 3058-3067.
120. Allen, C.; Maysinger, D.; Eisenberg, A. Nano-engineering block copolymer aggregates for drug delivery. Colloids Surf. B Biointerf., 1999, 16, 3-27.
121. Wong, H.L.; Bendayan, R.; Rauth, A.M.; Wu, X.Y. Development of solid lipid nanoparticles containing ionically complexed chemotherapeutic drugs and chemosensitizers. J. Pharm. Sci., 2004, 93, 1993-2008.
122. Borghouts, C.; Kunz, C.; Groner, B. Current strategies for the development of peptide-based anti-cancer therapeutics. J. Pept. Sci., 2005, 11, 713-726.
123. Pavlou, A.K.; Reichert, J.M. Recombinant protein therapeutics: Success rates, market trends and values to 2010. Nat. Biotechnol., 2004, 22, 1513-1519.
124. Kompella, U.B.; Lee, V.H.L. Pharmacokinetics of peptide and protein drugs. In: Peptide and Protein Drug Delivery; Lee, V. H. L. ed.; Marcel Dekker, New York, 1991, pp. 391-484.
125. Rabkin, R.; Dahl, D.C. Renal uptake and disposal of proteins and peptides. In: Biological Barriers in Protein Delivery; Audus, K. L., and Raub, T. J. ed.; Plenum Press, New York, 1993, pp. 299-338.
126. Zhang, Q.; Yie, G.; Li, Y.; Yang, Q.; Nagai, T. Studies on the cyclosporin A loaded stearic acid nanoparticles. Int. J. Pharm., 2000, 200, 153-159.
127. De Campos, A.M.; Sanchez, A.; Alonso, M.J. Chitosan nanoparticles. A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. Int. J. Pharm., 2001, 224, 159-168.
128. McLendon, P.M.; Fichter, K.M.; Reineke, T.M. Poly(glycoamidoamine) vehicles promote pDNA uptake through multiple routes and efficient gene expression via caveolae-mediated endocytosis. Mol. Pharmaceut., 2010, 7, 738-750.
129. Bhavsar, M.D.; Amiji, M.M. Polymeric nano- and microparticle technologies for oral gene delivery. Expert Opin. Drug Deliv., 2007, 4, 197-213.
130. Singh, R.; Lillard, J.W., Jr. Nanoparticle-based targeted drug delivery. Exp. Mol. Pathol., 2009, 86, 215-223.
131. Agueros, M.; Espuelas, S.; Esparza, I.; Calleja, P.; Penuelas, I.; Ponchel, G.; Irache, J.M. Cyclodextrin-poly(anhydride) nanoparticles as new vehicles for oral drug delivery. Expert Opin. Drug Deliv., 2011, 8, 721-734.
132. Bimbo, L.M.; Mäkilä, E.; Laaksonen, T.; Lehto, V.-P.; Salonen, J.; Hirvonen, J.; Santos, H.A. Drug permeation across intestinal epithelial cells using porous silicon nanoparticles. Biomaterials, 2011, 32, 2625-2633.
133. Woitiski, C.B.; Neufeld, R.J.; Veiga, F.; Carvalho, R.A.; Figueiredo, I.V. Pharmacological effect of orally delivered insulin facilitated by multilayered stable nanoparticles. Eur. J. Pharmaceut. Res., 2010, 41, 556-563.
134. Woitiski, C.B.; Sarmento, B.; Carvalho, R.A.; Neufeld, R.J.; Veiga, F. Facilitated nanoscale delivery of insulin across intestinal membrane models. Int. J. Pharm., 2011, 412, 123-131.
135. Yang, W.; Peters, J.I.; Williams III, R.O. Inhaled nanoparticles-A current review. Int. J. Pharmaceut., 2008, 356, 239-247.
136. Nosjean, O.; Briolay, A.; Roux, B. Mammalian GPI proteins: sorting, membrane residence and functions. Biochim. Biophys. Acta, 1997, 1331, 153-186.
137. Brewis, I.A.; Ferguson, M.A.J.; Mehlert, A.; Turner, A.J.; Hooper, N.M. Structures of the glycosyl-phosphatidylinositol anchors of porcine and human eythrocyte renal membrane dipeptidase. Comprehensive structural studies on the porcine anchor and interspecies comparison of the glycan core structures. J. Biol. Chem., 1995, 270, 22946-22956.
138. Ikezawa, H. Glyosylphosphatidylinositol (GPI)-anchored proteins. Biol. Pharm. Bull., 2002, 25, 409-417.
139. Tiede, A.; Bastisch, I.; Schubert, J.; Orlean, P.; Schmidt, R.E. Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes. Biol. Chem., 1999, 380, 503-523.
140. Orlean, P.; Menon, A.K. Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids. J. Lipid Res., 2007, 48, 993-1011.
141. Müller, G.; Wetekam, E.-M.; Jung, C.; Bandlow, W. Membrane association of lipoprotein lipase and a cAMP-binding ectoprotein in rat adipocytes. Biochemistry, 1994, 33, 12149-12159.
142. Müller, G.; Schulz, A.; Wied, S.; Frick, W. Regulation of lipid raft proteins by glimepiride- and insulin-induced glycosylphosphatidylinositol-specific phospholipase C in rat adipocytes. Biochem. Pharmacol., 2005, 69, 761-780.
143. Müller, G.; Jung, C.; Wied, S.; Welte, S.; Jordan, H.; Frick, W. Redistribution of glycolipid raft domain components induces insulin-mimetic signaling in rat adipocytes. Mol. Cell. Biol., 2001, 21, 4553-4567.
144. Müller, G.; Jung, C.; Wied, S. Translocation of glycosylphosphatidylinositol-anchored proteins from plasma membrane microdomains to lipid droplets in rat adipocytes is induced by palmitate, H2O2 and the sulfonylurea drug, glimepiride. Mol. Pharmacol., 2008, 73, 1513-1529.
145. Müller, G.; Wied, S.; Jung, C.; Over, S. Translocation of glycosylphosphatidylinositol-anchored proteins to lipid droplets and inhibition of lipolysis in rat adipocytes is mediated by reactive oxygen species. Br. J. Pharmacol., 2008, 154, 901-913.
146. Müller, G.; Over, S.; Wied, S.; Frick, W. Association of (c)AMPdegrading glycosylphosphatidylinositol-anchored proteins with lipid droplets is induced by palmitate, H2O2 and the sulfonylurea drug, glimepiride, in rat adipocytes. Biochemistry 2008, 47, 1274-1287.
147. Müller, G. Novel applications for glycosylphosphatidylinositolanchored proteins in pharmaceutical and industrial biotechnology. Mol. Membr. Biol., 2001, 28, 187-205.
148. Müller, G. Oral protein therapy for the future? Transport of glycolipid-modified therapeutic proteins. Pharmacology, 2010, 86, 92-116.
149. Müller, G. Oral delivery of protein drugs - Driver of personalized medicine? Curr. Issues Mol. Biol., 2010, 13, 13-24.
150. Müller, G. Control of lipid storage and cell size between adipocytes by vesicle-associated glycosylphosphatidylinositol-anchored proteins. Arch. Physiol. Biochem., 2011, 117, 23-43.
151. Premkumar, D.R.; Fukuoka, Y.; Sevlever, D.; Brunschwig, E.; Rosenberry, T.L.; Tykocinski, M.L. Properties of exogenously added GPI-anchored proteins following their incorporation into cells. J. Cell. Biochem., 2001, 82, 234-245.
152. Kooyman, D.L.; Byrne, G.W.; Logan, J.S. Glycosyl phosphatidylinositol anchor. Exp. Nephrol., 1998, 6, 148-151.
153. Medof, M.E.; Nagarajan, S.; Tykocinski, M.L. Cell-surface engineering with GPI-anchored proteins. FASEB J., 1996, 10, 574-586.
154. Civenni, G.; Test, S.T.; Brodbeck, U.; Bütikofer, P. In vitro incorporation of GPI-anchored proteins into human erythrocytes and their fate in the membrane. Blood, 1998, 9, 11784-11792.
155. McHugh, R.S.; Ahmed, S.N.; Wang, Y.C.; Sell, K.W.; Selvavaj, P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl. Acad. Sci. USA, 1995, 92, 8059-8063.
156. McHugh, R.S.; Nagarajan, S.; Wang, Y.C.; Sell, K.W.; Selvaraj, P. Protein transfer of glycosyl-phosphatidylinositol-B7-1 into tumor cell membranes: a novel approach to tumor immunotherapy. Cancer Res., 1999, 59, 2433-2437.
157. Ilangumaran, S.; Robinson, P.J.; Hoessli, D.C. Transfer of exogenous glycosylinositol (GPI)-linked molecules to plasma membranes. Trends Cell Biol., 1996, 6, 163-169.
158. Zhang, F.; Schmidt, W.G.; Hou, Y.; Williams, A.F.; Jacobson, K. Spontaneous incorporation of the glycosyl-phosphatidylinositollinked protein Thy-1 into cell membranes. Proc. Natl. Acad. Sci. USA, 1992, 89, 5231-5235.
159. Olschewski, D.; Seidel, R.; Miesbauer, M.; Rambold, A.S.; Oesterhelt, D.; Winklhofer, K.F.; Tatzelt, J.; Engelhard, M.; Becker, C.F. Semisynthetic murine prion protein equipped with a GPI anchor mimic incorporates into cellular membranes. Chem. Biol., 2007, 14, 994-1006.
160. Nosjean, O.; Roux, B. Ectoplasmic insertion of a glycosylphosphatidylinositol-anchored protein in glycosphingolipid- and cholesterol-containing phosphatidylcholine vesicles. Eur. J. Biochem., 1999, 263, 865-870.
161. Nosjean, O.; Roux, B. Anchoring of glycosylphosphatidylinositolproteins to liposomes. Methods Enzymol., 2003, 372, 216-232.
162. Morandat, S.; Bortolato, M.; Roux, B. Cholesterol-dependent insertion of glycosylphosphatidylinositol-anchored enzyme. Biochim. Biophys. Acta, 2002, 1564, 473-478.
163. Ronzon, F.; Morandat, S.; Roux, B.; Bortolato, M. Insertion of a glycosylphosphatidylinositol-anchored enzyme into liposomes. J. Membrane Biol., 2004, 197, 169-177.
164. Milhiet, P.-E.; Giocondi, M.-C.; Baghdadi, O.; Ronzon, F.; Roux, B.; Le Grimellec, C. Spontaneous insertion and partitioning of alkaline phosphatase into model lipid rafts. EMBO reports, 2002, 3, 485-490.
165. Müller, G.; Wied, S.; Jung, C.; Biemer-Daub, G.; Frick, W. Transfer of glycosylphosphatidylinositol-anchored 5'-nucleotidase CD73 from adiposomes into rat adipocytes stimulates lipid synthesis. Br. J. Pharmacol., 2010, 160, 878-891.
166. Müller, G.; Wied, S.; Over, S.; Frick, W. Inhibition of lipolysis by palmitate, H2O2 and the sulfonylurea drug, glimepiride, in rat adipocytes depends on cAMP degradation by lipid droplets. Biochemistry, 2008, 47, 1259-1273.
167. Müller, G.; Wied, S.; Dearey, E.-A.; Biemer-Daub, G. Glycosylphosphatidylinositol-anchored proteins coordinate lipolysis inhibition between large and small adipocytes. Metabolism, 2011, 60, 1021-1037.
168. Kooyman, D.L.; Byrne, G.W.; McClellan, S.; Nielsen, D.; Tone, M.; Waldmann, H.; Coffman, T.M.; McCurry, K.R.; Platt, J.L.; Logan, J.S. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science, 1995, 269, 89-92.
169. Suzuki, K.; Okumura, Y. GPI-linked proteins do not transfer spontaneously from erythrocytes to liposomes. New aspects of reorganization of the cell membrane. Biochemistry, 2000, 39, 9477-9485.
170. Brown, D.; London, L. Functions of lipid rafts in biological membranes. Annu. Rev. Cell. Dev. Biol., 1998, 14, 111-136.
171. Brown, D. Interactions between GPI-anchored proteins and membrane lipids. Trends Cell Biol., 1992, 2, 338-343.
172. Varma, R.; Mayor, S. GPI-anchored proteins are organized in submicron domains at the cell surface. Nature, 1998, 394, 798-801.
173. Simons, K.; Ikonen, E. Functional rafts in cell membranes. Nature, 1997, 387, 569-572.
174. Rajendran, L.; Simons, K. Lipid rafts and membrane dynamics. J. Cell Sci., 2005, 118, 1099-1102.
175. Brown, D.A.; Rose, J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. Cell, 1992, 68, 533-544.
176. Munro, S. Lipid rafts: elusive or illusive? Cell, 2003, 115, 377-388.
177. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol., 2000, 1, 31-39.
178. Müller, G.; Hanekop, N.; Wied, S.; Frick, W. Cholesterol depletion blocks redistribution of lipid raft components and insulin-mimetic signaling by glimepiride and phosphoinositolglycans in rat adipocytes. Mol. Med., 2002, 8, 120-136.
179. Danielsen, E.M.; Hansen, G.H. Lipid raft organization and function in the small intestinal brush border. J. Physiol. Biochem., 2008, 64, 377-382.
180. Danielsen, E.M.; Hansen, G.H. Lipid raft organization and function in brush borders of epithelial cells. Mol. Membr. Biol., 2006, 23, 71-79.
181. Ducharme, N.A.; Bickel, P.E. Lipid droplets in lipogenesis and lipolysis. Endocrinology, 2008, 149, 942-949.
182. Fujimoto, T.; Ohsaki, Y.; Cheng, J.; Suzuki, M.; Shinohara, Y. Lipid droplets: a classic organelle with new outfits. Histochem. Cell. Biol., 2008, 130, 263-279.
183. Ohsaki, Y.; Cheng, J.; Suzuki, M.; Shinohara, Y.; Fujita, A.; Fujimoto, T. Biogenesis of cytoplasmic lipid droplets: from the lipid ester globule in the membrane to the visible structure. Biochim. Biophys. Acta, 2009, 1791, 399-407.
184. Müller, G.; Petry, S. Triacylglycerol, storage and mobilization of human. In; Encyclopedia in Biochemistry and Molecular Biology; Meyers, A. Ed.; 2005, Wiley VCH, Weinheim, Germany, Vol. 14, pp. 621-704.
185. Boulant, S.; Targett-Adams, P.; McLauchlan, J. Disrupting the association of hepatitis C virus core protein with lipid droplets correlates with a loss in production of infectious virus. J. Gen. Virol., 2007, 88, 2204-2213.
186. Cocchiaro, J.; Kumar, Y.; Fischer, E.; Hackstadt, T.; Valdivia, R. Cytoplasmic lipid droplets are translocated into the lumen of the Chlamydia trachomatis parasitophorous vacuole. Proc. Natl. Acad. Sci. USA, 2008, 105, 9379-9384.
187. Cermelli, S.; Guo, Y.; Gross, S.; Welte, M. The lipid-droplet proteome reveals that droplets are a protein-storage depot. Curr. Biol., 2006, 16, 1783-1795.
188. Davis, M.E. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: From concept to clinic. Mol. Pharmaceut., 2009, 6, 659-668.
189. Xie, F.Y.; Woodle, M.C.; Lu, P.Y. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discovery Today, 2006, 11, 67-73.
190. Martin, S.E.; Caplen, N.J. Development of new RNAi therapeutics, Histol. Histopathol., 2007, 22, 211-217.
191. Leung, R.K.; Whittaker, P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther., 2005, 107, 222-239.
192. Kim, D.H.; Rossi, J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet., 2007, 8, 173-184.
193. Suda, T.; Suda, K.; Liu, D. Computer-assisted hydrodynamic gene delivery, Mol. Ther., 2008, 16, 1098-1104.
194. Gao, K.; Huang, L. Nonviral methods for siRNA delivery. Mol. Pharmaceut., 2009, 6, 651-658.
195. Cocucci, E.; Racchetti, G.; Meldolesi, J. Shedding microvesicles: artefacts no more. Trends Cell Biol., 2008, 19, 43-51.
196. Piccin, A.; Murphy, W.G.; Smith, O.P. Circulating microparticles: pathophysiology and clinical implications. Blood Rev., 2007, 21, 157-171.
197. Simons, M.; Raposo, G. Exosomes-vesicular carriers for intercellular communication. Curr. Opin. Cell Biol., 2009, 21, 575-581.
198. Shen, B.; Wu, N.; Yang, Jr. M.; Gould, S.J. Protein targeting to exosomes/microvesicles by plasma membrane anchors. J. Biol. Chem., 2011, 286, 14383-14395.
199. Valadi, H.; Ekström, K.; Bossios, A.; Sjöstrand, M.; Lee, J.J.; Lötvall, J.O. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol., 2007, 9, 654-659.
200. Camussi, G.; Deregibus, M.C.; Bruno, S.; Cantaluppi, V.; Biancone, L. Exosomes/microvesicles as a mechanism of cell-to-cell communication. Kidney Int., 2010, 78, 838-848.
201. Al-Nedawi, K.; Meehan, B.; Kerbel, R.S.; Allison, A.C.; Rak, J. Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR. Proc. Natl. Acad. Sci. USA, 2009, 106, 3794-3789.
202. Castellana, D.; Toti, F.; Freyssinet, J.M. Membrane microvesicles: Macromessengers in cancer disease and progression. Thrombosis Res., 2010, 125, S84-S88.
203. Yuan, A.; Farber, E.L.; Rapoport, A.L. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One, 2009, 4, e4722.
204. Heneghan, H.M.; Miller, N.; Kerin, M.J. Role of microRNAs in obesity and the metabolic syndrome. Obesity Rev., 2009, 11, 354-361.
205. Lin, Q.; Gao, Z.; Alarcon, R.M.; Ye, J.; Yun, Z. A role of miR-27 in the regulation of adipogenesis. FEBS J., 2009, 276, 2348-2358.
206. Esau, C.; Kang, X.; Peralta, E.; Hanson, E.; Marcusson, E.G.; Ravichandran, L. V.; Sun, Y.; Koo, S.; Perera, R.J.; Jain, R.; Dean, N.M.; Freier, S.M.; Bennet, C.F.; Lollo, B., Griffey, R. MicroRNA-143 regulates adipocyte differentiation. J. Biol. Chem., 2004, 279, 52361-52365.
207. Xie, H.; Lim, B.; Lodish, H.F. MicroRNAs induced during adipogenesis that accelerate fat cell development are downregulated in obesity. Diabetes, 2009, 58, 1050-1057.
208. Ortega, F.J.; Moreno-Navarrete, J.M.; Pardo, G.; Sabater, M.; Hummel, M.; Ferrer, A.; Rodriguez-Hermosa, J.I.; Ruiz, B.; Ricart, W.; Pera, B.; Fernandez-Real, J.M. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One, 2010, 5, e9022.
209. Müller, G.; Schneider, M.; Biemer-Daub, G.; Wied, S. Microvesicles released from rat adipocytes and harboring glycosylphosphatidylinositol-anchored proteins transfer RNA stimulating lipid synthesis. Cell Signal., 2011, 23, 1207-1223.
210. Müller, G.; Wied, S.; Jung, C.; Frick, W.; Biemer-Daub, G. Inhibition of lipolysis by adiposomes containing glycosylphosphatidylinositol-anchored Gce1 protein in rat adipocytes. Arch. Physiol. Biochem., 2010, 116, 28-41.
211. Aoki, N.; Jin-no, S.; Nakagawa, Y.; Asai, N.; Arakawa, E.; Tamura, N.; Tamura T.; Matsuda, T. Identification and characterization of microvesicles secreted by 3T3-L1 adipocytes: redox-and hormone-dependent induction of milk fat globule-epidermal growth factor 8-associated microvesicles. Endocrinology, 2007, 148, 3850-3862.
212. Ogawa, R.; Tanaka, C.; Stao, M. Nagasaki, H; Sugimura, K; Okumura, K; Nakagawa, Y; Aoki N. Adipocyte-derived microvesicles contain RNA that is transported into macrophages and might be secreted into blood circulation. Biochem. Biophys. Res. Commun., 2010, 398, 723-729.
213. Müller, G.; Wied, S.; Schneider, M. Regulation of lipid synthesis between large and small rat adipocytes by glycosylphosphatidylinositol-anchored CD73. Obesity, 2011, 19, 1531-1544.
214. Müller, G.; Wied, S.; Jung, C.; Straub, J. Coordinated regulation of esterification and lipolysis by palmitate, H2O2 and the anti-diabetic sulfonylurea drug, glimepiride, in rat adipocytes. Eur. J. Pharmacol., 2008, 597, 6-18.
215. Cao, J.; Li, J.L.; Li, D.; Tobin, J.F.; Gimeno, R.E. Molecular identification of microsomal acyl-CoA:glycerol-3-phosphate acyltransferase, a key enzyme in de novo triacylglycerol synthesis. Proc. Natl. Acad. Sci. USA, 2006, 103, 19695-19700.
216. Nishino, N.; Tamori, Y.; Tateya, S.; Kawaguchi, T.; Shibakusa, T. FSP27 contributes to efficient energy storage in murine white adipocytes by promoting the formation of unilocular lipid droplets. J. Clin. Invest., 2008, 118, 2808-2821.
217. Puri, V.; Ranjit, S.; Konda, S.; Nicoloro, S.M.; Straubhaar, J.; Chawla, A.; Chouinard, M.; Lin, C.; Burkart, A.; Corvera, S.; Perugini, R.A.; Czech, M.P. Cidea is associated with lipid droplets and insulin sensitivity in humans. Proc. Natl. Acad. Sci. USA, 2008, 105, 7833-7838.
218. Heerwagen, M.J.R.; Miller, M.R.; Barbour, L.A.; Friedman, J.E. Maternal obesity and fetal metabolic programming: a fertile epigenetic soil. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2010, 299, R711-R722.
219. Stöger, R. Epigenetics and obesity. Pharmacogenomics, 2008, 9, 1851-1860.
220. Jenuwein, T.; Allis, C.D. Translating the histone code. Science, 2001, 293, 1074-1080.
221. Schreiber, S.L.; Bernstein, B.E. Signaling network model of chromatin. Cell, 2002, 111, 771-778.
222. Martin, C.; Zhang, Y. The diverse functions of histone lysine modification. Nat. Rev. Mol. Cell Biol., 2005, 6, 838-849.
223. Campion, J.; Milagro, F.I.; Martinez, J.A. Individuality and epigenetics in obesity. Obesity Rev., 2009, 10, 383-392.
224. Parra, P.; Serra, F.; Palou, A. Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One, 2010, 5, e13005.
225. Cho, Y.-W.; Hong, S.H.; Jin, Q.; Wang, L.; Lee, J.E.; Gavrilova, O.; Ge, K. Histone methylation regulator PTIP is required for PPARα and C/EBP_ expression and adipogenesis. Cell Metab., 2009, 10, 27-39.
226. Musri, M.M.; Carmona, M.C.; Hanzu, F.A.; Kaliman, P.; Gomis, R.; Parrizas, M. Histone demethylase LSD1 regulates adipogenesis. J. Biol. Chem., 2010, 285, 30034-30041.
227. Welsch, S.; Keppler, O.T.; Habermann, A.; Allespach, I.; Krijnse-Locker, J.; Krausslich, H.G. HIV-1 buds predominantly at the plasma membrane of primary human macrophages. PLoS Pathog., 2007, 3, e36.
228. Zacharias, D.A.; Violon, J.D.; Newton, A.C.; Tsien, R.Y. Partitioning of lipid-modified monomeric GFPs into membrane microdomains of live cells. Science, 2002, 296, 913-916.
229. Saksena, S.; Sun, J.; Chu, T.; Emr, S.D. ESCRTing proteins in the endocytic pathway. Trends Biochem. Sci., 2007, 32, 561-573.
230. Booth, A.M.; Fang, Y.; Fallon, J.K.; Yang, Y.M.; Hildreth, J.E.; Gould, S.J. Exosomes and HIV Gag bud from endosome-like domains of the T cell plasma membrane. J. Cell Biol., 2006, 172, 923-935.
231. Leventhal, I.; Grzybek, M.; Simons, K. Greasing their way: lipid modifications determine protein association with membrane rafts. Biochemistry, 2010, 49, 6305-6316.
232. Toh, S.Y.; Gong, J.; Du, G.; Li, J.Z.; Yang, S.; Ye, J.; Yao, H.; Zhang, Y.; Xue, B.; Li, Q. Up-regulation of mitochondrial activity and acquirement of brown adipose tissue-like property in the white adipose tissue of fsp27 deficient mice. PLoS One, 2008, 3, e2890.
233. Kuypers, F.A.; Larkin, S.K.; Emeis, J.J.; Allison, A.C. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent anti-thrombotic activity. Thromb. Haemost., 2007, 97, 478-486.
234. Salti, I. and the Diabetes and Ramadan Study Group. Efficacy and safety of insulin glargine and glimepiride in subjects with type 2 diabetes before, during and after the period of fasting in Ramadan. Diabet. Med., 2009, 26, 1255-1261.
235. Gottschalk, M.; Danne, T.; Vlajnic, A.; Cara, J.F. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care, 2007, 30, 790-794.
236. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.-J.; Preat, V. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J. Control. Rel., 2006, 116, 1-27.
237. Alexis, F.; Pridgen, E.; Molnar, L.K.; Farokhzad, O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharmaceut., 2008, 4, 505-515.
238. Li, S.-D.; Huang, L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharmaceut., 2008; 5, 496-504.
239. Rajendran, L.; Knölker, H.-J.; Simons, K. Subcellular targeting strategies for drug design and delivery. Nat. Rev. Drug Discovery, 2010, 9, 29-42.
240. Müller, G. Personalized strategies for the diagnosis and therapy of type II diabetes and obesity. Immunol. Endocrin. Metabol. Agents Med. Chem., 2012, 12(2), 80-109.
241. Gesta, S.; Tseng, Y.H.; Kahn, C.R. Developmental origin of fat: tracking obesity to its source. Cell, 2007, 131, 242-256.
242. Gurdon, J.B. Adult frogs derived from the nuclei of single somatic cells. Develop. Biol., 1962, 4, 256-273.
243. Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126, 663-676.
244. Zhou, Q.; Brown, J.; Kanarek, A.; Rajagopal, J.; Melton, D.A. In vivo reprogramming of adult pancreatic exocrine cells to ß-cells. Nature, 2008, 455, 627-632.
245. Vierbuchen, T.; Ostermerier, A.; Pang, Z.P.; Kokubu, Y.; Südhof, T.; Wernig, M Direct conversion of fibroblasts to functional neurons by defined factors. Nature, 2010, 463, 1035-1041.
246. Ieda, M.; Fu, J.D.; Delgado-Olguin, P.; Vedantham, V.; Hayashi, Y.; Bruneau, B.G.; Srivastava, D. Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell, 2010, 142, 375-386.
247. Waddington, C.H. The strategy of the genes. A discussion of some aspects of theoretical biology. Alen & Unwin, USA, 1957.
248. Davidson, E.H. The regulatory genome: gene regulatory networks in development and evolution. Academic Proess, USA, 2006.
249. Warren, L.; Manos, P.D.; Ahfeldt, T.; Loh, Y-H.; Li, H.; Lau, F.; Ebina, W.; Mandal, P.K.; Smith, Z.D.; Meissner, A.; Daley, G.Q.; Brack, A.S.; Collins, J.J.; Cowan, C.; Schlaeger, T.M.; Rossi, D.J. Highly efficient reprogramming to pluripotency and directed differentiation of uhman cells with synthetic modified mRNA. Cell Stem Cell, 2010, 7, 618-630.
250. Wadia, J.S.; Dowdy, S.F. Protein transduction technology. Curr. Opin. Biotechnol., 2002, 13, 52-56.
251. Brown, K.C. New approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial libraries. Curr. Opin. Chem. Biol., 2000, 4, 16-21.
252. Song, E.; Zhu, P.; Lee, S.-K., Chowdhury, D.; Kussmann, S.; Dykxhoorn, D.M.; Feng, Y.; Palliser, D.; Weiner, D.B.; Shankar, P.; Marasco, W.A.; Lieberman, J. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nature Biotech., 2005, 23, 709-717.
253. Zhou, H.; Wu, S.; Joo, J.Y.; Zhu, S.; Han, D.W.; Lin, T.; Trauger, S.; Bien, G.; Yao, S.; Zhu, Y.; Siuzdak, G.; Schöler, H.R.; Duan, L.; Ding, S. Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell, 2009, 4, 581-588.
254. Ber, I.; Shternhall, K.; Perl, S.; Ohanuna, Z.; Goldberg, I.; Bar-shack, I.; Benvisti-Zarum, L.; Meivar-Levy, I.; Ferber, S. Functional, persistent and extended liver to pancreas transdifferentiation. J. Biol. Chem., 2003, 278, 31950-31957.
255. McCarroll, S.A.; Altshuler, D.M. Copy-number variation and association studies of human disease. Nat. Genet., 2007, 39, S37-S42.
256. Jain, K.K. Proteomics: delivering new routes to drug discovery - Part 1. Drug Discov. Today, 2001, 6, 772-774.
257. Meier, M.; Hummel, M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc. Health Risk Manag., 2009, 5, 859-871.
258. McCarthy, M.I. Genomics, type 2 diabetes, and obesity. N. Engl. J. Med., 2010, 363, 2339-2350.
259. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007, 447, 661-678.
260. Zeggini, E.; Scott, L.J.; Saxena, R. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat. Genet., 2008, 40, 638-645.
261. Mihaescu, R.; van Hoek, K.; Sijbrands, E.J. Evaluation of risk prediction updates from commercial genome-wide scans. Genet. Med., 2009, 11, 588-594.
262. Pearson, E.R. Pharmacogenetics in diabetes. Curr. Diab. Rep., 2009, 9, 172-181.
263. Flotte, T.R. Gene therapy for cystic fibrosis. Curr. Opin. Mol. Ther., 1999, 1, 510-516.
264. Bates, S. Progress towards personalized medicine. Drug Discov. Today, 2010, 15, 115-120.